Results 201 to 210 of about 1,371 (289)

Establishment of Human Formative Pluripotent Stem Cell‐Like Cells Exhibiting Amniotic Differentiation Potentials

open access: yesCell Proliferation, EarlyView.
The hfPSC‐LCs could be established from naïve hESCs, conventional hESCs, hiPSCs, and human blastocysts. The hfPSC‐LCs hold robust capacity for three germ layers, hPGCLCs, and hALPCs. ABSTRACT Human embryos undergo pivotal morphogenetic remodelling shortly after implantation. The understanding of this crucial stage is severely impeded by the scarcity of
Xiaoxiao Wang   +11 more
wiley   +1 more source

A Curcumin‐Derived HSP70 Inhibitor Disrupts Lysosomal Function to Suppress Triple‐Negative Breast Cancer Progression

open access: yesCell Proliferation, EarlyView.
Novel curcumin‐derived M4 binds HSP70's ATPase domain, disrupting HSP70‐mediated lysosomes‐autophagy pathway to inhibit TNBC growth and metastasis, and synergizes with paclitaxel for potent combination therapy. ABSTRACT Structural modification of curcumin yielded a novel series of 1,4‐pentadien‐3‐one oxime ether derivatives, among which compound M4 ...
Zijian Li   +6 more
wiley   +1 more source

Tunnelling Nanotube‐Mediated Lysosome Sharing Promotes Osteocyte Survival via Transcellular Autophagy

open access: yesCell Proliferation, EarlyView.
This study provides the first definitive identification of tunnelling nanotubes (TNTs) between cultured osteocytes and shows TNT‐mediated lysosome transfer from healthy to stressed cells, restoring autophagic flux and preventing apoptosis. This discovery of transcellular autophagy reveals a new survival mechanism in osteocytes, offering potential ...
Jinbiao Qiang   +16 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock   +5 more
wiley   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger   +6 more
wiley   +1 more source

Antimicrobial prescribing guidelines for feedlot cattle

open access: yes
Australian Veterinary Journal, EarlyView.
P Cusack   +4 more
wiley   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger   +5 more
wiley   +1 more source

The circulation and distribution of classical Greek coinage

open access: yesThe Economic History Review, EarlyView.
Abstract From a sample of the most prominent Greek city‐states, data involving a total of 999 hoards and 160,007 coins from 550 to 300 BC were collected to discern the relative magnitudes, consistency of issue, and distribution of Classical Greek coinages.
Zane Mullins
wiley   +1 more source

Home - About - Disclaimer - Privacy